Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.47 |
| ▸ | EGFR | P00533 | 10/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30878675 | 0.92 | MAP4K1 (0.48) | MAP4K1EGFRFLT3BTKBLK | |
| SCHEMBL30878664 | 0.92 | MAP4K1 (0.51) | MAP4K1EGFRBTKJAK3 | |
| SCHEMBL30878812 | 0.90 | BTK (0.49) | MAP4K1EGFRBTKJAK3BLK | |
| SCHEMBL30878864 | 0.88 | MAP4K1 (0.50) | MAP4K1EGFRFLT3BTKBLK | |
| SCHEMBL30879138 | 0.88 | BTK (0.43) | MAP4K1EGFRBTKJAK3BLK | |
| SCHEMBL30878843 | 0.87 | BTK (0.47) | MAP4K1EGFRBTKJAK3BLK | |
| SCHEMBL30878878 | 0.87 | BTK (0.54) | EGFRBTKAKT3JAK3BLK | |
| SCHEMBL30878364 | 0.87 | MAP4K1 (0.51) | MAP4K1EGFRFLT3BTKAKT3 | |
| SCHEMBL30878821 | 0.85 | EGFR (0.47) | MAP4K1EGFRBTK | |
| SCHEMBL30878668 | 0.85 | EGFR (0.41) | MAP4K1EGFRFLT3BTKAKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |